Press Release 2021 - Sami-Sabinsa Group | Formerly Known as Sami Labs Limited

Disclaimer

US-FDA: This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Usage disclaimer: The information pertaining to any marketing materials by Sabinsa, is for general purposes only. Users are urged to check the validity of patents if any, on any Sabinsa items for their intended use.

EFSA: This statement has not been evaluated by the EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Australia: Please note as an ingredient supplier the information contained in this website is for marketers of finished products formulations and is not intended as consumer advice. Marketers should ensure finished products are lawful and comply with the regulations of the countries in which these items are sold. Every care has been taken to ensure the accuracy of the information provided at the time of publication.

Sami-Sabinsa to Introduce New Products and the Most Recent Book on Ashwagandha by Dr. Muhammed Majeed at SupplySide West

Sami-Sabinsa to Showcase New Products, Host Event at Vitafoods Europe

Sami-Sabinsa’s Postbiotic LactoSporin® Wins 1st Place in NIE Awards

Sami-Sabinsa Names Dr. Umar Jan as President of European Operations

Sami-Sabinsa Expands UK and EU Footprint with New Staff

Sami-Sabinsa Reaches Intellectual Property Milestone with over 300 Patents Granted

About

Certificates

Global Contacts List

Get in Touch